Guselkumab (Tremfya)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses guselkumab (Tremfya) 100 mg/mL in a 1 mL pre-filled syringe or patient-controlled injector. Indication: For the treatment of adult patients with active psoriatic arthritis. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (DMARD) (e.g., methotrexate).